South Koreas Hanmi Pharmaceutical said Friday that Sanofi has signaled the start of two new phase 3 clinical studies of the Type 2 diabetes drug candidate efpeglenatide by officially listing the plans on ClinicalTrials.gov, a US-based clinical trials registry site.
By doing so, Sanofi has officially executed all five of its planned phase 3 clinical trial agenda for efpeglenatide, which Hanmi licensed out to Sanofi in 2015, according to the Korean drugmaker.
So far, Sanofi has been carrying out three phase 3 clinical studies — one to discern the effect of efpeglenatide on cardiovascular outcomes, another to compare the drugs efficacy to a placebo and another to compare efpeglenatide with Dulaglutide.
Now, two types of new clinical trials have begun. One study aims to compare efpeglenatides efficacy and safety in treating type 2 diabetes that is inadequately controlled with metformin alone or in combination with sulfonylurea.
The other study compares the diabetes drug candidates efficacy and safety in treating type 2 diabetes that is inadequately controlled with basal insulin alone or in combination with an oral antidiabetic drug.
Around 6,400 patients will participate in the five Sanofi-led efpeglenatide studies, which will conclude in the first half of 2021, according to the companies.
Developed by South Koreas Hanmi Pharmaceutical, efpeglenatide is a once-weekly GLP-1 receptor agonist for treating Type II diabetes. The drug candidate was licensed out to Sanofi in November 2015.
Efpeglenatide employs Hanmis Lapscovery — short for Long Acting Protein and Peptide Discovery — delivery technology, which extends the life of a peptide or protein in the body, extending efficacy and potency.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.